scholarly journals Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study

Author(s):  
Melissa S. Y. Thong ◽  
Daniela Doege ◽  
Linda Weißer ◽  
Lena Koch-Gallenkamp ◽  
Heike Bertram ◽  
...  

Abstract Purpose Limited research suggests that cancer survivors have problems with insurance. Our study aimed to gain insight into the proportion of very long-term (14–24 years post-diagnosis) survivors of breast, colorectal, and prostate cancers who had problems with health (HI) and life (LI) insurance. Methods We used data from CAESAR (CAncEr Survivorship—A multi-Regional population-based study). Participants completed questions on change in insurance providers since cancer diagnosis, problems with requesting (additional) HI or LI, and how potential problems were resolved. We conducted logistic regression to determine factors associated with change in statutory HI. Results Of the 2714 respondents, 174 (6%) reported having changed HI providers. Most switched between different statutory HI providers (86%), 9% from statutory to private, and 5% from private to statutory. Respondents who changed statutory HI providers were more likely to be prostate cancer survivors (OR 2.79, 95% CI 1.01–7.68) while being ≥ 65 years at time of diagnosis (OR 0.58, 95% CI 0.35–0.96) and having ≥ 2 comorbid conditions (OR 0.61, 95% CI 0.40–0.92) were associated with reduced odds for change. Problems in changing HI were minimal and were resolved with additional contribution. Of the 310 respondents who tried to get LI, 25 respondents reported having difficulties, of whom the majority had their request rejected. Conclusion Most cancer survivors did not change their HI nor tried to buy LI after cancer diagnosis. Problems with changing statutory HI were generally resolved with additional contribution while the main problem encountered when buying LI was rejection of request.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10073-10073
Author(s):  
Mia Hashibe ◽  
Yuji Chen ◽  
Brenna Blackburn ◽  
Yuan Wan ◽  
Kerry G. Rowe ◽  
...  

10073 Background: In the US, there are approximately 235,200 ovarian cancer survivors today. Five-year survival for ovarian cancer has increased from 36% for women who were diagnosed in 1975-1977 to 46% for women diagnosed between 2005-2011. Long term follow-up studies among ovarian cancer survivors are uncommon and late effects have not been well characterized in a population-based cohort. Although genitourinary complications during treatment are well known, long term impacts need to be investigated. Methods: A total of 602 first primary invasive ovarian cancer cases diagnosed between 1996-2012 who survived for > 5 years were identified in the Utah Population Database and compared to a general population cohort of women. Genitourinary disease diagnoses were identified through ICD codes from hospital electronic medical records and statewide ambulatory surgery and inpatient data. Cox regression models were used to estimate hazard ratios for disease risks by time since cancer diagnosis with adjustments on matching factors, baseline BMI, baseline Charlson Comorbidity Index (CCI), and race. Results: The overall risk of genitourinary diseases for ovarian cancer patients in comparison to the general population cohort was 1.51 (95%CI = 1.30-1.74) 5-10 years after cancer diagnosis. Approximately 54.6% of ovarian cancer survivors were diagnosed with a genitourinary disease 5-10 years after cancer diagnosis. The most common genitourinary diseases among the ovarian cancer survivors were urinary tract infections (10.1%), acute renal failure (5.5%), and chronic kidney disease (4.4%). The greatest risks were observed for hydronephrosis (HR = 10.65, 95%CI = 3.68-30.80), pelvic peritoneal adhesions (HR = 5.81, 95%CI = 1.11-30.39), cystitis and urethritis (HR = 2.67, 95%CI = 1.21-6.38), and acute renal failure (HR = 2.30, 95%CI = 1.36-3.88). Conclusions: Ovarian cancer survivors experience increased risks of various genitourinary diseases in the 5-10 year period following cancer diagnosis. Understanding the multimorbidity trajectory among ovarian cancer survivors is of vital importance to improve their clinical care after cancer diagnosis and allow for increased attention to these potential late effects.


Author(s):  
Floortje Mols ◽  
Ida J. Korfage ◽  
Ad J.J.M. Vingerhoets ◽  
Paul J.M. Kil ◽  
Jan Willem W. Coebergh ◽  
...  

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 9594-9594
Author(s):  
Anne-Valérie Guizard ◽  
Clarisse Kerleau ◽  
Pascale Grosclaude ◽  
Mariette Mercier ◽  
Natacha Heutte ◽  
...  

2016 ◽  
Vol 63 ◽  
pp. 143-153 ◽  
Author(s):  
Clarisse Kerleau ◽  
Anne-Valérie Guizard ◽  
Laetitia Daubisse-Marliac ◽  
Natacha Heutte ◽  
Mariette Mercier ◽  
...  

2007 ◽  
Vol 121 (4) ◽  
pp. 871-877 ◽  
Author(s):  
Floortje Mols ◽  
Kazimier A. Helfenrath ◽  
Ad J.J.M. Vingerhoets ◽  
Jan Willem W. Coebergh ◽  
Lonneke V. van de Poll-Franse

2013 ◽  
Vol 12 (6) ◽  
pp. 160-161
Author(s):  
W. Schaake ◽  
M. De Groot ◽  
W. Krijnen ◽  
J.A. Langendijk ◽  
A.C.M. Van Den Bergh

2019 ◽  
Vol 15 (5) ◽  
Author(s):  
Jianqiu Kong ◽  
Xiayao Diao ◽  
Feiyu Diao ◽  
Xinxiang Fan ◽  
Junjiong Zheng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document